For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Over the last six months, Angle has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for the ...

Over the last six months, ANGLE has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for the ...

Following the Jan. 13 announcement, Illumina shares jumped 5.5% to close at $144.22 on Monday. The company has democratized sequencing over the past 20 years, and with the progress in AI and ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted significant advancements ...

Leading American genomic sequencing firm Illumina is the first biotech company on Beijing’s list. More than 60 per cent of the world’s genetic sequencing data is generated by Illumina’s ...

Meanwhile, it doesn't seem coincidental that Illumina, which is the most significant genetic sequencing business in the world, has a large Chinese rival in biotech BGI Genomics. Ever feel like you ...

Illumina is down 15.2% since the beginning of the year, and at $111.06 per share, it is trading 28.4% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of ...

Illumina has struggled to boost sales and consistently deliver positive earnings. Its Q4 report was largely a disappointment, and management's 2025 guidance came in below Wall Street's ...